[go: up one dir, main page]

DK3326645T3 - Fremgangsmåder til bestemmelse af forskelle i alpha-4-integrinaktivitet ved korrelation af forskelle i svcam- og/eller smadcam-niveauer - Google Patents

Fremgangsmåder til bestemmelse af forskelle i alpha-4-integrinaktivitet ved korrelation af forskelle i svcam- og/eller smadcam-niveauer Download PDF

Info

Publication number
DK3326645T3
DK3326645T3 DK17192860.9T DK17192860T DK3326645T3 DK 3326645 T3 DK3326645 T3 DK 3326645T3 DK 17192860 T DK17192860 T DK 17192860T DK 3326645 T3 DK3326645 T3 DK 3326645T3
Authority
DK
Denmark
Prior art keywords
differences
svcam
alpha
correlation
methods
Prior art date
Application number
DK17192860.9T
Other languages
English (en)
Inventor
Alissa A Chackerian
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Application granted granted Critical
Publication of DK3326645T3 publication Critical patent/DK3326645T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/7056—Selectin superfamily, e.g. LAM-1, GlyCAM, ELAM-1, PADGEM
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DK17192860.9T 2010-10-25 2011-10-24 Fremgangsmåder til bestemmelse af forskelle i alpha-4-integrinaktivitet ved korrelation af forskelle i svcam- og/eller smadcam-niveauer DK3326645T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40635810P 2010-10-25 2010-10-25
US40636510P 2010-10-25 2010-10-25
EP11838481.7A EP2632492B1 (en) 2010-10-25 2011-10-24 METHODS FOR DETERMINING DIFFERENCES IN ALPHA-4 INTEGRIN ACTIVITY BY CORRELATING DIFFERENCES IN sVCAM AND/OR sMAdCAM LEVELS

Publications (1)

Publication Number Publication Date
DK3326645T3 true DK3326645T3 (da) 2020-06-15

Family

ID=46024768

Family Applications (2)

Application Number Title Priority Date Filing Date
DK17192860.9T DK3326645T3 (da) 2010-10-25 2011-10-24 Fremgangsmåder til bestemmelse af forskelle i alpha-4-integrinaktivitet ved korrelation af forskelle i svcam- og/eller smadcam-niveauer
DK20162844.3T DK3722808T3 (da) 2010-10-25 2011-10-24 Fremgangsmåder til bestemmelse af forskelle i alpha-4-integrinaktivitet ved korrelation af forskelle i svcam- og/eller smadcam-niveauer

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK20162844.3T DK3722808T3 (da) 2010-10-25 2011-10-24 Fremgangsmåder til bestemmelse af forskelle i alpha-4-integrinaktivitet ved korrelation af forskelle i svcam- og/eller smadcam-niveauer

Country Status (18)

Country Link
US (3) US20130337470A1 (da)
EP (3) EP2632492B1 (da)
JP (2) JP5847188B2 (da)
AU (4) AU2011323820A1 (da)
CA (1) CA2816016A1 (da)
CY (1) CY1123060T1 (da)
DK (2) DK3326645T3 (da)
ES (3) ES2800066T3 (da)
FI (1) FI3722808T3 (da)
HR (2) HRP20241666T1 (da)
HU (2) HUE069385T2 (da)
LT (2) LT3326645T (da)
PL (2) PL3722808T3 (da)
PT (2) PT3722808T (da)
RS (2) RS66261B1 (da)
SI (2) SI3722808T1 (da)
SM (2) SMT202400498T1 (da)
WO (1) WO2012061074A1 (da)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011323820A1 (en) 2010-10-25 2013-05-23 Biogen Ma Inc. Methods for determining differences in alpha-4 integrin activity by correlating differences in sVCAM and/or sMAdCAM levels
EP3227685A1 (en) * 2014-12-02 2017-10-11 Nestec S.A. Methods for establishing a vedolizumab dosing regimen to treat patients with irritable bowel disease
TW202504919A (zh) 2023-05-30 2025-02-01 美商派拉岡醫療公司 α4β7整合素抗體組合物及使用方法

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5338689A (en) 1987-08-24 1994-08-16 Stiftung Fur Diagnostische Forschung Method and card for detecting antigens and/or antibodies
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5730978A (en) 1989-09-01 1998-03-24 Fred Hutchinson Cancer Research Center Inhibition of lymphocyte adherence with α4β1-specific antibodies
US7238668B1 (en) 1989-09-01 2007-07-03 Fred Hutchinson Cancer Research Center Inhibition of lymphocyte adherence with CS-1-peptides and fragments thereof
US6033665A (en) 1989-09-27 2000-03-07 Elan Pharmaceuticals, Inc. Compositions and methods for modulating leukocyte adhesion to brain endothelial cells
US5260210A (en) 1989-09-27 1993-11-09 Rubin Lee L Blood-brain barrier model
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9206318D0 (en) 1992-03-24 1992-05-06 Cambridge Antibody Tech Binding substances
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
DE69230142T2 (de) 1991-05-15 2000-03-09 Cambridge Antibody Technology Ltd. Verfahren zur herstellung von spezifischen bindungspaargliedern
US6225447B1 (en) 1991-05-15 2001-05-01 Cambridge Antibody Technology Ltd. Methods for producing members of specific binding pairs
LU91067I2 (fr) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
US5224539A (en) 1991-06-14 1993-07-06 Coen Company, Inc. Cooling system for air heaters and the like
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5885793A (en) 1991-12-02 1999-03-23 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
US5872215A (en) 1991-12-02 1999-02-16 Medical Research Council Specific binding members, materials and methods
US5871734A (en) 1992-01-13 1999-02-16 Biogen, Inc. Treatment for asthma with VLA-4 blocking agents
US5932214A (en) 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
EP0678122B1 (en) 1993-01-12 1999-07-28 Biogen, Inc. Recombinant anti-vla4 antibody molecules
CA2155303C (en) 1993-02-09 2010-04-20 Linda C. Burkly Treatment for insulin dependent diabetes
US7435802B2 (en) 1994-01-25 2008-10-14 Elan Pharaceuticals, Inc. Humanized anti-VLA4 immunoglobulins
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
GB9406974D0 (en) 1994-04-08 1994-06-01 Pharmaceutical Proteins Ltd Transgenic production
BE1008817A6 (fr) 1994-10-28 1996-08-06 Univ Bruxelles Procede d'obtention d'adn bicatenaire membranaire humain, produit obtenu par ce procede et trousse de diagnostic le contenant.
US6113898A (en) 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
GB9712818D0 (en) 1996-07-08 1997-08-20 Cambridge Antibody Tech Labelling and selection of specific binding molecules
DE19647381A1 (de) 1996-11-15 1998-05-20 Hoechst Ag Neue Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten
PL323130A1 (en) 1996-11-15 1998-05-25 Hoechst Ag Application of heterocyclic compounds in production of a pharmaceutic agent, novel heterocyclic compounds and pharmaceutic agent as such
US5965356A (en) 1997-01-31 1999-10-12 University Of Maryland, Baltimore Herpes simplex virus type specific seroassay
US6489300B1 (en) * 1997-07-31 2002-12-03 Eugene D. Thorsett Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4
DE19741235A1 (de) 1997-09-18 1999-03-25 Hoechst Marion Roussel De Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19741873A1 (de) 1997-09-23 1999-03-25 Hoechst Marion Roussel De Gmbh Neue 5-Ring-Heterocyclen, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19751251A1 (de) 1997-11-19 1999-05-20 Hoechst Marion Roussel De Gmbh Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate
ES2321994T3 (es) * 1998-05-13 2009-06-15 Genentech, Inc. Diagnostico y tratamiento de trastornos hepaticos.
DE19821483A1 (de) 1998-05-14 1999-11-18 Hoechst Marion Roussel De Gmbh Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19922462A1 (de) 1999-05-17 2000-11-23 Aventis Pharma Gmbh Spiro-imidazolidinderivate, ihre Herstellung ihre Verwendung und sie enthaltende pharmazeutische Präparate
US6756378B2 (en) 1999-06-30 2004-06-29 Pharmacopeia Drug Discovery, Inc. VLA-4 inhibitor compounds
CN1413210A (zh) 1999-12-28 2003-04-23 辉瑞产品公司 用于治疗炎症、自身免疫性疾病和呼吸系统疾病的vla－4依赖性细胞结合的非肽基抑制剂
AU2001287000A1 (en) * 2000-09-01 2002-03-13 The Center For Blood Research, Inc. Modified polypeptides stabilized in a desired conformation and methods for producing same
DE10111877A1 (de) 2001-03-10 2002-09-12 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE10137595A1 (de) 2001-08-01 2003-02-13 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung und ihre Verwendung
ES2531852T3 (es) 2002-02-25 2015-03-20 Biogen Idec Ma Inc. Administración de agentes para el tratamiento de la inflamación
EP2484381A1 (en) 2003-01-24 2012-08-08 Elan Pharmaceuticals Inc. Composition for a treatment of demyelinating diseases and paralysis by administration of remyelinating agents
AU2004210679A1 (en) 2003-02-10 2004-08-26 Elan Pharmaceuticals, Inc. Immunoglobulin formulation and method of preparation thereof
EP2394652A3 (en) 2004-02-06 2012-10-24 Elan Pharmaceuticals Inc. Methods and compositions for treating tumors and metastatic disease
MY162179A (en) 2004-04-01 2017-05-31 Elan Pharm Inc Steroid sparing agents and methods of using same
AU2005231467A1 (en) 2004-04-01 2005-10-20 Elan Pharmaceuticals, Inc. Steroid sparing agents and methods of using same
US7196112B2 (en) 2004-07-16 2007-03-27 Biogen Idec Ma Inc. Cell adhesion inhibitors
MX2007010971A (es) 2005-03-08 2007-09-19 Pharmacia & Upjohn Co Llc Composiciones de anticuerpo anti-citla-4.
US8124350B2 (en) * 2005-04-04 2012-02-28 Biogen Idec Ma Inc. Methods and products for evaluating an immune response to a therapeutic protein
WO2007100770A2 (en) 2006-02-28 2007-09-07 Elan Pharmaceuticals, Inc. Methods of treating inflammatory and autoimmune diseases with natalizumab
WO2007103112A2 (en) 2006-03-03 2007-09-13 Elan Pharmaceuticals, Inc. Methods of treating inflammatory and autoimmune diseases with natalizumab
CA2708262A1 (en) 2007-12-07 2009-06-18 Elan Pharmaceuticals, Inc. Methods and compositions for treating liquid tumors
CA2723614C (en) * 2008-05-16 2015-07-14 Genentech, Inc. Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists
WO2009141786A2 (en) 2008-05-21 2009-11-26 Piramal Life Sciences Limited Anti-inflammatory compounds
WO2010053316A2 (en) 2008-11-06 2010-05-14 Snu R&Db Foundation New use of sixth immunoglobulin-like domain of vcam-1
NZ577731A (en) * 2009-06-16 2010-08-27 Innate Therapeutics Ltd Compositions and methods for treatment of multiple sclerosis
WO2011137418A1 (en) * 2010-04-30 2011-11-03 Elan Pharmaceuticals, Inc. Selective integrin inhibitors
AU2011323820A1 (en) 2010-10-25 2013-05-23 Biogen Ma Inc. Methods for determining differences in alpha-4 integrin activity by correlating differences in sVCAM and/or sMAdCAM levels

Also Published As

Publication number Publication date
CY1123060T1 (el) 2021-10-29
HK1256157A1 (en) 2019-09-13
FI3722808T3 (fi) 2024-12-10
PT3326645T (pt) 2020-06-23
EP3326645A1 (en) 2018-05-30
AU2011323820A1 (en) 2013-05-23
US20220206012A1 (en) 2022-06-30
RS60565B1 (sr) 2020-08-31
JP2014500950A (ja) 2014-01-16
ES2654820T3 (es) 2018-02-15
US20160291035A1 (en) 2016-10-06
EP2632492B1 (en) 2017-10-04
HUE069385T2 (hu) 2025-03-28
HRP20200920T1 (hr) 2020-10-30
US20130337470A1 (en) 2013-12-19
HUE050713T2 (hu) 2020-12-28
AU2021212059B2 (en) 2025-02-27
ES2800066T3 (es) 2020-12-23
JP2015215363A (ja) 2015-12-03
WO2012061074A1 (en) 2012-05-10
SI3326645T1 (sl) 2020-09-30
DK3722808T3 (da) 2024-12-09
EP2632492A1 (en) 2013-09-04
AU2019204089A1 (en) 2019-07-04
SMT202400498T1 (it) 2025-01-14
EP2632492A4 (en) 2014-04-02
AU2017201658A1 (en) 2017-03-30
CA2816016A1 (en) 2012-05-10
AU2021212059A1 (en) 2021-08-26
PL3722808T3 (pl) 2025-02-03
EP3722808B1 (en) 2024-09-11
EP3326645B1 (en) 2020-03-18
HRP20241666T1 (hr) 2025-02-14
SMT202000380T1 (it) 2020-09-10
SI3722808T1 (sl) 2025-02-28
ES2997080T3 (en) 2025-02-14
PT3722808T (pt) 2024-12-09
EP3722808A1 (en) 2020-10-14
LT3326645T (lt) 2020-08-10
PL3326645T3 (pl) 2020-09-21
US11079393B2 (en) 2021-08-03
RS66261B1 (sr) 2024-12-31
LT3722808T (lt) 2024-12-27
AU2017201658B2 (en) 2019-03-21
JP5847188B2 (ja) 2016-01-20

Similar Documents

Publication Publication Date Title
DK2676118T3 (da) Fremgangsmåde til fiksering af vævsprøve
DK3511423T4 (da) Fremgangsmåder og produkt til optimering af lokaliseret eller rumlig detektion af genekspression i en vævsprøve
DK3643795T3 (da) Fremganffremgangsmåde til bestemmelse af celle- eller vævsdød ved analyse af dna-methylering
DK3412687T3 (da) Fremgangsmåder til behandling af dlbcl
EP2788722A4 (en) FLIGHT FORECAST SYSTEM
BR112012029417A2 (pt) detecção de análise de ataques maliciosos
CO6811822A2 (es) Análisis de riesgos de infraestructura energética y remediación
BR112013024467A2 (pt) método e composições direcionadas para células adiposas em mamíferos
DK2638149T3 (da) Immortalisering af epitelceller og fremgangsmåder til anvendelse
DK3195793T3 (da) Forbedringer i eller relateret til oftalmologi
FR2953220B1 (fr) Signature microarn de la differenciation epidermique et utilisations
RS55804B1 (sr) Testovi za adrenomedulin i metodi za određivanje zrelog adrenomedulina
IL231442A0 (en) Measurement of a fluorescent analyte using tissue excitation
BR112014000329A2 (pt) método de análise de distúrbios cardiovasculares e uso do mesmo
DK3581199T3 (da) Fremgangsmåder til behandling eller reduktion af ødematøs fibrosklerotisk pannikulitis
DK2814835T3 (da) Enzymer og fremgangsmåder til spaltning af N-glycaner fra glycoproteiner
FI20115308L (fi) Menetelmä sairauskohtausten havaitsemiseksi tai ennustamiseksi
BRPI1011394A8 (pt) método para avaliação de responsividade de linforma de células b ao tratamento com anticorpos anti-cd40
DK2646011T3 (da) Fremgangsmåder til reduktion af overspisning eller tvangsspisning
EP2656275A4 (en) WHEEL SLIP SIMULATION SYSTEMS AND METHODS
DK2715310T3 (da) Fremgangsmåde til påvisning og mængdebestemmelse af et målmolekyle i et væv
BRPI1010684A2 (pt) método para determinar o potencial cardiorregenerativo de células mamíferas
DK2723886T3 (da) Bestemmelse af direkte thrombininhibitorer i serum eller urin
DK3326645T3 (da) Fremgangsmåder til bestemmelse af forskelle i alpha-4-integrinaktivitet ved korrelation af forskelle i svcam- og/eller smadcam-niveauer
DK3461807T3 (da) Design og udvikling af hidtil ukendte detergenter til anvendelse i pcr-systemer